PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 7544748-4 1995 Using a cytotoxicity assay and a radioimmunoassay, we observed significant increases in levels of tumor necrosis factor-alpha (TNF-alpha) in the colitis mucosa and detected interleukin-1 alpha in the mucosa of 3 of 5 DSS rats and an increase in TNF-alpha had a tendency to be inhibited by treatment with FK506. Tacrolimus 304-309 tumor necrosis factor Rattus norvegicus 98-125 7544748-4 1995 Using a cytotoxicity assay and a radioimmunoassay, we observed significant increases in levels of tumor necrosis factor-alpha (TNF-alpha) in the colitis mucosa and detected interleukin-1 alpha in the mucosa of 3 of 5 DSS rats and an increase in TNF-alpha had a tendency to be inhibited by treatment with FK506. Tacrolimus 304-309 tumor necrosis factor Rattus norvegicus 127-136 7516291-0 1994 Evidence that FK506 alleviates ischemia/reperfusion injury to the rat liver: in vivo demonstration for suppression of TNF-a production in response to endotoxemia. Tacrolimus 14-19 tumor necrosis factor Rattus norvegicus 118-123 30713033-10 2019 RESULTS: In rats pre-treated with FK506, the levels of transaminases, TNF-alpha and IL-1beta were reduced significantly and also liver damage was dramatically mitigated compared to those without FK506 pre-treatment. Tacrolimus 34-39 tumor necrosis factor Rattus norvegicus 70-79 1374948-8 1992 FK506 pretreatment significantly reduced the serum levels of BUN (P less than 0.02), creatinine (P less than 0.02), and TNF (P less than 0.05) as compared with that seen in controls. Tacrolimus 0-5 tumor necrosis factor Rattus norvegicus 120-123 1374948-11 1992 Based upon these data, it can be concluded that (1) FK506 pretreatment ameliorates the functional renal injury associated with I/R, (2) renal ischemia induces the release of TNF, and (3) FK506 pretreatment results in a significant inhibition of TNF production. Tacrolimus 52-57 tumor necrosis factor Rattus norvegicus 174-177 1374948-11 1992 Based upon these data, it can be concluded that (1) FK506 pretreatment ameliorates the functional renal injury associated with I/R, (2) renal ischemia induces the release of TNF, and (3) FK506 pretreatment results in a significant inhibition of TNF production. Tacrolimus 52-57 tumor necrosis factor Rattus norvegicus 245-248 31572289-11 2019 Besides, FK506 also significantly reduced the levels of factors involved in inflammatory response such as vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1), tumor necrosis factor-alpha (TNF-alpha), and Protein Kinase C delta (PKCdelta) that rise after epilepsy. Tacrolimus 9-14 tumor necrosis factor Rattus norvegicus 194-221 31572289-11 2019 Besides, FK506 also significantly reduced the levels of factors involved in inflammatory response such as vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1), tumor necrosis factor-alpha (TNF-alpha), and Protein Kinase C delta (PKCdelta) that rise after epilepsy. Tacrolimus 9-14 tumor necrosis factor Rattus norvegicus 223-232 22004713-10 2011 In addition, FK506 markedly reduced microglial activation (P<0 01) and TNF-alpha expression (P<0 01). Tacrolimus 13-18 tumor necrosis factor Rattus norvegicus 75-84 23334350-1 2013 BACKGROUND: We aimed to compare the effects of intraperitoneal ghrelin and tacrolimus on vitreous levels of tumor necrosis factor-alpha (TNF-alpha), interleukin-1 (IL-1), and interleukin-6 (IL-6) in an experimental autoimmune uveitis model. Tacrolimus 75-85 tumor necrosis factor Rattus norvegicus 108-135 23334350-14 2013 CONCLUSIONS: Tacrolimus could be effective in uveitis treatment by neutralizing or decreasing the levels of cytokines such as TNF-alpha, IL-1 and IL-6 that have a critical part in the pathogenesis of uveitis. Tacrolimus 13-23 tumor necrosis factor Rattus norvegicus 126-135 21820512-9 2011 Reduced mRNA expression levels of CD4, IFN-gamma, IL-6, IL-10, iNOS, NFkappaB, TNF-alpha and MCP-1 (p <= 0.05) were observed in tacrolimus treated animals compared to sirolimus. Tacrolimus 131-141 tumor necrosis factor Rattus norvegicus 79-88 21255669-11 2011 Tacrolimus treatment diminished TNF-alpha but not IL-1 expression increase after LPS challenge in hepatic tissue. Tacrolimus 0-10 tumor necrosis factor Rattus norvegicus 32-41 21255669-13 2011 Plasmatic NO, CO, TNF-alpha, and IL-1 concentrations increase after LPS challenge was diminished when highest doses of tacrolimus were given. Tacrolimus 119-129 tumor necrosis factor Rattus norvegicus 18-27 19728359-6 2009 FK506 also lowered the protein levels of TNFalpha and IL-2 in ischemic brain areas. Tacrolimus 0-5 tumor necrosis factor Rattus norvegicus 41-49 20402659-10 2010 Treatment with all three drugs (tacrolimus, somatostatin and glucocorticoids) resulted in a significant decrease of serum amylase, lung edema, and serum TNF-alpha and IL-1beta levels. Tacrolimus 32-42 tumor necrosis factor Rattus norvegicus 153-162 19952532-5 2009 Pretreatment with tacrolimus also produced significant (p<0.05) reduction in TBARS, total calcium, TNF-alpha, IL-8 and MPO whereas it showed an increase in GSH level at higher dose. Tacrolimus 18-28 tumor necrosis factor Rattus norvegicus 102-111 17367747-6 2007 Tacrolimus treatment in periodontitis-induced rats conferred protection against the inflammation-induced tissue and bone loss associated with periodontitis, through a mechanism involving IL-1beta, TNF-alpha and IL-6. Tacrolimus 0-10 tumor necrosis factor Rattus norvegicus 197-206 17367747-5 2007 More specifically, Tacrolimus suppressed the expression of serum interleukin (IL-1beta), tumour necrosis factor (TNF-alpha), IL-6, airpouch exudate PGE(2) and leukocytosis usually observed after the induction of periodontitis. Tacrolimus 19-29 tumor necrosis factor Rattus norvegicus 113-122 10385251-3 1999 Tacrolimus, formerly known as FK506, is a macrolide antibiotic, that blocks the transcription of several proinflammatory cytokines including TNF-alpha. Tacrolimus 0-10 tumor necrosis factor Rattus norvegicus 141-150 16868484-9 2006 Whereas IFN-gamma and FK506 treatment lead to an enhanced intrapancreatic and systemic TNF-alpha protein release during the early course, IL-1beta concentrations were significantly reduced within the late intervals. Tacrolimus 22-27 tumor necrosis factor Rattus norvegicus 87-96 14991082-1 2003 OBJECTIVE AND DESIGN: To determine the effect of FK506 (tacrolimus) on paw inflammation, TNF-alpha expression in joint, and bone and cartilage destruction in type II collagen-induced arthritis (CIA) model in rats. Tacrolimus 56-66 tumor necrosis factor Rattus norvegicus 89-98 14991082-10 2003 FK506 (3.2 mg/kg) markedly reduced TNF-alpha expression. Tacrolimus 0-5 tumor necrosis factor Rattus norvegicus 35-44 14991082-14 2003 CONCLUSION: These results show that FK506 is effective in suppressing inflammation, TNF-alpha expression in joint, and damage to bone and cartilage in rat CIA, and may be useful in the treatment of rheumatoid arthritis. Tacrolimus 36-41 tumor necrosis factor Rattus norvegicus 84-93 11812963-12 2002 Moreover, tacrolimus increased survival time (118 +/- 7 minutes; P <.01) and survival rate (vehicle = 0 and tacrolimus = 90% 240 minutes after bleeding was discontinued), reverted the marked hypotension, decreased liver messenger RNA for TNF-alpha reduced plasma TNF-alpha (35 +/- 6 pg/mL), and restored the hyporeactivity to phenylephrine to control values. Tacrolimus 10-20 tumor necrosis factor Rattus norvegicus 241-250 11812963-12 2002 Moreover, tacrolimus increased survival time (118 +/- 7 minutes; P <.01) and survival rate (vehicle = 0 and tacrolimus = 90% 240 minutes after bleeding was discontinued), reverted the marked hypotension, decreased liver messenger RNA for TNF-alpha reduced plasma TNF-alpha (35 +/- 6 pg/mL), and restored the hyporeactivity to phenylephrine to control values. Tacrolimus 10-20 tumor necrosis factor Rattus norvegicus 266-275 11045663-9 2000 The optimal doses of CsA and tacrolimus had similar inhibitory effects on Th1 type cytokine IL-2 and interferon [INF]-gamma), inflammatory cytokine (IL-1beta and tumor necrosis factor [TNF]-alpha), and cytotoxic factor (granzyme B and perforin) mRNA expression. Tacrolimus 29-39 tumor necrosis factor Rattus norvegicus 185-195 17612778-8 2007 This study shows that conversion from CsA to tacrolimus therapy leads to a reversal of the CsA-induced bone loss, which can probably be mediated by downregulation of IL-1beta, IL-6, and TNF-alpha production. Tacrolimus 45-55 tumor necrosis factor Rattus norvegicus 186-195 15390105-8 2005 In FK506-treated rats, a significant reduction of IL-1beta, IL-6, and TNF-alpha expression was observed 12 h after reperfusion. Tacrolimus 3-8 tumor necrosis factor Rattus norvegicus 70-79 15390105-10 2005 FK506 selectively decreased the levels of TNF-alpha, and IL-1beta mRNAs in astrocytes in vitro, with no effect on transforming growth factor-beta 1 (TGF-beta1) and IL-6 expression. Tacrolimus 0-5 tumor necrosis factor Rattus norvegicus 42-51 14528517-8 2003 FK506 caused a marked reduction of TNF-a and IL-1beta levels in paw tissue even in short-term (3-day) therapeutic treatment. Tacrolimus 0-5 tumor necrosis factor Rattus norvegicus 35-40 14528517-12 2003 CONCLUSION: FK506 is more effective than MTX in reducing elevated levels of inflammatory cytokines TNF-a, IL-1beta, and IL-6 in established stages of AIA. Tacrolimus 12-17 tumor necrosis factor Rattus norvegicus 99-104 11117573-8 2000 The serum TNF-alpha concentration was lower in the FK 506-treated group (1,419 +/- 957 pg/ml) than in the saline group (9205 +/- 2215) (P < 0.01). Tacrolimus 51-57 tumor necrosis factor Rattus norvegicus 10-19 10961655-1 2000 We compared in rats with 6-hydroxydopamine (6-OHDA)-induced hemiparkinsonism the content of tumor necrosis factor (TNF)-alpha in the nigrostriatal dopaminergic region of the control side with that of the 6-OHDA-injected experimental side, and explored the effects of 6-OHDA injection combined with the immunosuppressant FK506 treatment (0.5 or 4 mg/kg per day for 2 weeks). Tacrolimus 320-325 tumor necrosis factor Rattus norvegicus 92-125 10961655-2 2000 The ratios of the concentration of TNF-alpha in the striatum and substantia nigra on the 6-OHDA injection side to that on the control side in the 6-OHDA hemiparkinsonism rats were significantly higher than those in the control rats without 6-OHDA treatment, whereas those in the rats treated with 6-OHDA and FK506 were not significantly different from those in the control rats. Tacrolimus 308-313 tumor necrosis factor Rattus norvegicus 35-44 10961655-3 2000 Thus FK506 attenuated increased TNF-alpha level in the nigrostriatal dopaminergic region injured by 6-OHDA treatment. Tacrolimus 5-10 tumor necrosis factor Rattus norvegicus 32-41 10685002-7 2000 FK506 as well as steroids inhibited TNF-alpha and IL-4 production by RBL-1 cells. Tacrolimus 0-5 tumor necrosis factor Rattus norvegicus 36-45 10385251-3 1999 Tacrolimus, formerly known as FK506, is a macrolide antibiotic, that blocks the transcription of several proinflammatory cytokines including TNF-alpha. Tacrolimus 30-35 tumor necrosis factor Rattus norvegicus 141-150 10385251-12 1999 Tacrolimus (100 microg kg(-1), 5 min after splanchnic arteries occlusion) increased survival rate (SAO + Tacrolimus = 100% at 4 h of reperfusion), reverted the marked hypotension, reduced serum TNF-alpha (15+/-3 U ml(-1)), ameliorated leukopenia, reduced ileal MPO (0.9+/-0.01 U g(-1) tissue), restored to control values the hyporeactivity to PE. Tacrolimus 0-10 tumor necrosis factor Rattus norvegicus 194-203 9754866-7 1998 TNF-alpha release induced by DTBHQ and CPA was inhibited by treatment with actinomycin-D, the immunosuppressant FK506 and the glucocorticoid dexamethasone (p < or = 0.01). Tacrolimus 112-117 tumor necrosis factor Rattus norvegicus 0-9 9325011-4 1997 The dependence on Ca2+ in the induction of GM-CSF, but not of apoptosis, was further confirmed by the inhibition of TNF- or IL-1-induced cytokine production by cyclosporin A or FK506, drugs that block the Ca2+/calmodulin-dependent protein Ser/Thr phosphatase calcineurin. Tacrolimus 177-182 tumor necrosis factor Rattus norvegicus 116-119 8665940-7 1996 Low concentrations (2 nM) of okadaic acid, a serine/threonine phosphatase inhibitor, prevented TNF-alpha-induced inhibition of MAPK and restored insulin"s effect on MAPK activity, while orthovanadate (a tyrosine phosphatase inhibitor), inhibitor 2 (phosphatase-1 inhibitor) and FK506 (phosphatase-2B inhibitor) were ineffective. Tacrolimus 278-283 tumor necrosis factor Rattus norvegicus 95-104